Incyte
- Country
- πΊπΈUnited States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- Biological: Daratumumab SC
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 15
- Registration Number
- NCT03837509
- Locations
- πΊπΈ
New York Oncology Hematology, Albany, New York, United States
πΊπΈVirginia Cancer Specialists-Fairfax, Fairfax, Virginia, United States
πΊπΈDana Farber Cancer Institute, Boston, Massachusetts, United States
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2023-03-20
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 111
- Registration Number
- NCT03822117
- Locations
- πΊπΈ
Massachusetts General Hospital, Boston, Massachusetts, United States
πΊπΈCancer Treatment Centers of America, Zion, Illinois, United States
πΊπΈCarle Cancer Center, Urbana, Illinois, United States
A Study of the Safety and Tolerability of INCB050465 in Pemphigus Vulgaris
- First Posted Date
- 2018-12-19
- Last Posted Date
- 2019-09-13
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03780166
A Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB086550 in Participants With Advanced Solid Tumors
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 138
- Registration Number
- NCT03762447
- Locations
- π«π·
Icm Montpellier, Montpellier Cedex 5, France
π«π·Institut Universitaire Du Cancer de Toulouse Oncopole, Toulouse, France
πΊπΈJefferson University Hospitals, Philadelphia, Pennsylvania, United States
TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 618
- Registration Number
- NCT03745651
- Locations
- πΊπΈ
Jubilee Clinical Research - BTC - PPDS, Las Vegas, Nevada, United States
πΊπΈCenter For Dermatology Cosmetic And Laser Surgery, Fremont, California, United States
πΊπΈSynexus Clinical Research US Inc. Santa Rosa, Santa Rosa, California, United States
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 631
- Registration Number
- NCT03745638
- Locations
- πΊπΈ
First OC Dermatology, Fountain Valley, California, United States
πΊπΈDermatology Specialists Inc, Oceanside, California, United States
πΊπΈIntegrated Research Group Inc., Riverside, California, United States
Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects
- Conditions
- Acute Graft-versus-host Disease
- Interventions
- Drug: Corticosteroids
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 2
- Registration Number
- NCT03721965
- Locations
- πΊπΈ
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
πΊπΈDuke University Medical Center, Durham, North Carolina, United States
πΊπΈUniversity Hospitals Cleveland Medical Center - Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
- Conditions
- Relapsed Diffuse Large B-Cell LymphomaRefractory Diffuse Large B-Cell Lymphoma
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT03688152
- Locations
- πΊπΈ
UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
πΊπΈUniversity of Arizona Cancer Center, Tucson, Arizona, United States
πΊπΈClinical Research Alliance, Lake Success, New York, United States
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
- Conditions
- Metastatic Non-small Cell Lung CancerMetastatic MelanomaLocally Advanced Renal Cell CarcinomaLocally Advanced Urothelial CancerMetastatic Urothelial CancerUnresectable MelanomaMetastatic Clear-Cell Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 121
- Registration Number
- NCT03679767
- Locations
- πΊπΈ
Texas Oncology - Waco, Waco, Texas, United States
π¦πΉLKH Graz, Graz, Austria
πΊπΈCalifornia Cancer Associates for Research and Excellence, Inc., San Marcos, California, United States
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
- Conditions
- Unresectable CholangiocarcinomaMetastatic Cholangiocarcinoma
- Interventions
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 167
- Registration Number
- NCT03656536
- Locations
- πΊπΈ
Parkview Research Center, Fort Wayne, Indiana, United States
πΊπΈBeth Israel Deaconess Medical Center, Boston, Massachusetts, United States
πΊπΈUniversity Hospitals Cleveland Medical Center, Cleveland, Ohio, United States